[1] Wang W, Zhao C Y, Zhou J Y, et al. Invasive pulmonary aspergillosis in patients with HBV-related liver failure[J]. Eur J Clin Microbiol Infect Dis, 2011, 30(5): 661-667.
[2] 赵彩彦,张苹苹,周俊英,等. 重型肝炎合并侵袭性肺曲霉感染死亡五例[J]. 中华临床感染病杂志, 2008, 1(5): 301-302.
[3] 赵彩彦,王亚东. 重症肝病合并侵袭性真菌感染的若干问题[J]. 中华临床感染病杂志, 2009, 02(6): 381-384.
[4] Tr D, Np K. Pathogenesis of Aspergillus fumigatus in Invasive Aspergillosis[J]. Clin Microbiol Rev, 2009, 22(3):447-465.
[5] Chakrabarti A, Chatterjee SS, Das A, et al. Invasive aspergillosis in developing countries[J]. Med Mycol, 2011, 49(S1): S35-S47.
[6] Garnacho-Montero J, Olaechea P, Alvarez-Lerma F, et al. Epidemiology, diagnosis and treatment of fungal respiratory infections in the critically ill patient[J]. Rev Esp Quimioter, 2013, 26(2): 173-188.
[7] Lahmer T, Peçanha-Pietrobom P M, Schmid R M, et al. Invasive fungal infections in acute and chronic liver impairment: A systematic review[J]. Mycoses, 2022, 65(2): 140-151.
[8] Zen M, Canova M, Campana C, et al. The kaleidoscope of glucorticoid effects on immune system[J]. Autoimmun Rev, 2011, 10(6): 305-310.
[9] Xue R, Meng Q. The Management of Glucocorticoid Therapy in Liver Failure[J]. Front Immun, 2019, 10: 2490.
[10] 孟庆华. 糖皮质激素治疗肝衰竭的时机把握[J]. 临床肝胆病杂志, 2017, 33 (09): 1683-1686.
[11] Kousha M, Tadi R, Soubani A O. Pulmonary aspergillosis: a clinical review[J]. Eur Respir Rev, 2011, 20(121): 156-174.
[12] Nucci M, Nouér S A, Cappone D, et al. Early diagnosis of invasive pulmonary aspergillosis in hematologic patients: an opportunity to improve the outcome[J]. Haematologica, 2013, 98(11): 1657-1660.
[13] Donnelly J P, Chen S C, Kauffman C A, et al. Revision and Update of the Consensus Definitions of Invasive Fungal Disease From the European Organization for Research and Treatment of Cancer and the Mycoses Study Group Education and Research Consortium[J]. Clin Infect Dis, 2020, 71(6): 1367-1376.
[14] 谢婧,申川,李子月,等. 泊沙康唑对肝衰竭患者侵袭性肺曲霉病的预防性治疗[J]. 中华传染病杂志, 2023, 41(11): 706-713.
[15] O'Flynn R, Zhou Y P, Waskin H, et al. Hepatic safety of the antifungal triazole agent posaconazole: characterization of adverse event reports in a manufacturer's safety database[J]. Expert Opin Drug Saf, 2022, 21(8): 1113-1120.
[16] Maertens J A, Rahav G, Lee D G, et al. Posaconazole versus voriconazole for primary treatment of invasive aspergillosis: a phase 3, randomised, controlled, non-inferiority trial[J]. Lancet, 2021, 397(10273): 499-509.
[17] Patterson T F, Thompson G R, Denning D W, et al. Practice Guidelines for the Diagnosis and Management of Aspergillosis: 2016 Update by the Infectious Diseases Society of America[J]. Clin Infect Dis, 2016, 63(4): e1-e60.
[18] 中国研究型医院学会肝病专业委员会重症肝病学组,中华医学会肝病学分会重型肝病与人工肝学组. 重症肝病合并侵袭性真菌感染诊治专家共识[J]. 中华肝脏病杂志, 2022, 30(2): 159-168.
[19] Chen K, Zhang X, Ke X, et al. Individualized Medication of Voriconazole: A Practice Guideline of the Division of Therapeutic Drug Monitoring, Chinese Pharmacological Society[J]. Therapeutic Drug Monitoring, 2018, 40(6): 663-674.
[20] Jin H, Wang T, Falcione B A, et al. Trough concentration of voriconazole and its relationship with efficacy and safety: a systematic review and meta-analysis[J].J Antimicrob Chemother, 2016, 71(7): 1772-1785. |
